---
title: "These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295423642.md"
description: "ANI Pharmaceuticals reported strong Q2 earnings, beating estimates with $2.21 EPS and $266M sales, while affirming FY2026 guidance. Despite positive results, shares fell 3.2%. Analysts slashed price targets: Canaccord Genuity lowered its target to $90 (Hold), and Guggenheim cut its target to $119 (Buy)."
datetime: "2026-08-10T14:39:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295423642.md)
  - [en](https://longbridge.com/en/news/295423642.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295423642.md)
generator: "portal-rs"
---

# These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

**ANI Pharmaceuticals Inc** (NASDAQ:ANIP) reported upbeat earnings for the second quarter on Friday.

The company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share. The company reported quarterly sales of $266.044 million which beat the analyst consensus estimate of $260.128 million.

ANI Pharmaceuticals affirmed FY2026 adjusted EPS guidance of $9.19-$9.69 and also affirmed sales forecast of $1.080 billion-$1.140 billion.

“In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history,” said Nikhil Lalwani, President and CEO of ANI. “Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing. The encouraging initial trends we are seeing from the gout expansion, and the continued momentum in our existing specialties, further support our conviction in Cortrophin Gel’s sizable multi-year growth opportunity.”

ANI Pharmaceuticals shares fell 3.2% to trade at $75.73 on Monday.

These analysts made changes to their price targets on ANI Pharmaceuticals following earnings announcement.

-   Canaccord Genuity analyst Gary Nachman maintained the stock with a Hold and lowered the price target from $91 to $90.
-   Guggenheim analyst Vamil Divan maintained the stock with a Buy and cut the price target from $124 to $119.

**Considering buying ANIP stock? Here’s what analysts think:**

*Photo via Shutterstock*

### Related Stocks

- [ANIP.US](https://longbridge.com/en/quote/ANIP.US.md)

## Related News & Research

- [Globeflex Capital L P Takes Position in ANI Pharmaceuticals, Inc. $ANIP](https://longbridge.com/en/news/296757387.md)
- [ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors  | ANIP Stock News](https://longbridge.com/en/news/296776694.md)
- [BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now?](https://longbridge.com/en/news/296688974.md)
- [Great Lakes Advisors LLC Acquires Shares of 29,800 Supernus Pharmaceuticals, Inc. $SUPN](https://longbridge.com/en/news/296676820.md)
- [$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296632631.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**